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Axonal transport deficits precede structural loss in glaucoma and other
neurodegenerations. Impairments in structural support, including modified cytoskeletal
proteins, and microtubule-destabilizing elements, could be initiating factors in glaucoma
pathogenesis. We investigated the time course of changes in protein levels and
post-translational modifications in the DBA/2J mouse model of glaucoma. Using
anterograde tract tracing of the retinal projection, we assessed major cytoskeletal
and transported elements as a function of transport integrity in different stages of
pathological progression. Using capillary-based electrophoresis, single- and multiplex
immunosorbent assays, and immunofluorescence, we quantified hyperphosphorylated
neurofilament-heavy chain, phosphorylated tau (ptau), calpain-mediated spectrin
breakdown product (145/150 kDa), β–tubulin, and amyloid-β42 proteins based on
age and transport outcome to the superior colliculus (SC; the main retinal target in
mice). Phosphorylated neurofilament-heavy chain (pNF-H) was elevated within the
optic nerve (ON) and SC of 8–10 month-old DBA/2J mice, but was not evident in the
retina until 12–15 months, suggesting that cytoskeletal modifications first appear in the
distal retinal projection. As expected, higher pNF-H levels in the SC and retina were
correlated with axonal transport deficits. Elevations in hyperphosphorylated tau (ptau)
occurred in ON and SC between 3 and 8 month of age while retinal ptau accumulations
occurred at 12–15 months in DBA/2J mice. In vitro co-immunoprecipitation experiments
suggested increased affinity of ptau for the retrograde motor complex protein dynactin.
We observed a transport-related decrease of β-tubulin in ON of 10–12 month-old
DBA/2J mice, suggesting destabilized microtubule array. Elevations in calpain-mediated
spectrin breakdown product were seen in ON and SC at the earliest age examined,
well before axonal transport loss is evident. Finally, transport-independent elevations
of amyloid-β42, unlike pNF-H or ptau, occurred first in the retina of DBA/2J mice, and
then progressed to SC. These data demonstrate distal-to-proximal progression of
cytoskeletal modifications in the progression of glaucoma, with many of these changes
occurring prior to complete loss of functional transport and axon degeneration. The
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earliest changes, such as elevated spectrin breakdown and amyloid-β levels, may make
retinal ganglion cells susceptible to future stressors. As such, targeting modification of
the axonal cytoskeleton in glaucoma may provide unique opportunities to slow disease
progression.
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INTRODUCTION
Glaucoma is a major cause of irreversible blindness, predicted
to aﬄict nearly 112 million people worldwide by the year
2020 (Tham et al., 2014). While age and sensitivity to elevated
intraocular pressure (IOP) are two major risk factors, ultimately
it is the dysfunction and degeneration of retinal ganglion cells
and their axons that lead to permanent vision loss in glaucoma
(Quigley, 1999; Almasieh et al., 2012). As in many other
chronic neurodegenerations, axonopathy is a component of early
glaucoma pathogenesis (Libby et al., 2005; McKinnon et al., 2009;
Crish et al., 2010; Dengler-Crish et al., 2014; Cooper et al., 2016).
Furthermore, axonopathy is compartmentalized, with axonal
transport deficits, morphological changes, and eventual axon loss
initially manifested in the distal segments of retinal ganglion
cell (RGC) axons (Libby et al., 2005; Schlamp et al., 2006; Crish
et al., 2010, 2013; Dengler-Crish et al., 2014; Cooper et al.,
2016). Functional axonal transport deficits are observed before
structural loss—wherein lies a therapeutic window separating the
earliest elements of dysfunction in this disease from stages of
irrevocable neural loss (Crish et al., 2010; Sunico et al., 2011;
Dengler-Crish et al., 2014).
Axonal transport blockade has been linked to aberrant
cytoskeletal organization or breakdown (Coleman, 2005; Shea
and Chan, 2008), and cytoskeletal proteins have been historically
used as pathological markers in glaucoma (Soto et al., 2011).
Recent work has redirected attention to these elements as
potential mechanisms for disease progression (Balaratnasingam
et al., 2008; Kang et al., 2014; Cooper et al., 2016). In the DBA/2J
mouse, a well-characterized model that develops progressive
glaucomatous pathology as a function of age (John et al.,
1998), optic nerves (ON) from pathologically-advanced mice
show striking evidence of large swellings (spheroids) exhibiting
accumulated cargo and disorganized, highly phosphorylated
neurofilaments (Crish et al., 2010). However, the nature and time
course of cytoskeletal abnormalities within the axon have not
been clearly defined; these changes may explain the underlying
mechanics of early axonal transport deficits characteristic of
glaucoma.
The axonal cytoskeleton is dynamic, and arrangement of
its components is tightly regulated to produce the proper
organization essential for normal structure and function of
the axon (Köpke et al., 1993; Nicolas et al., 2002; Ackerley
et al., 2003; Jung et al., 2005; Song et al., 2013; Xu et al.,
2013; Wortman et al., 2014). Axonopathy often begins with
Abbreviations: pNF-H, hyperphosphorylated heavy-chain neurofilament; SBDP,
spectrin breakdown product; ON, optic nerve; SC, superior colliculus; GSK,
glycogen synthase kinase; RGC, retinal ganglion cell.
post-translational modifications of proteins involved in axon
structure and function (Petzold et al., 2008). Aberrations in
several cytoskeletal proteins, such as neurofilaments, spectrin,
microtubules, and tau, have been implicated in the pathogenesis
of neurodegenerative diseases, including glaucoma (Braak et al.,
1994; Schultz et al., 1997; Ahlijanian et al., 2000; Fischer et al.,
2004; Tahzib et al., 2004; Cuchillo-Ibanez et al., 2008; Petzold
et al., 2008; Chidlow et al., 2011; Haines et al., 2011; Ito et al.,
2012; Yan and Jeromin, 2012). Amyloid-β (Aβ) has been a
biomarker of neurodegenerationmost commonly associated with
Alzheimer’s disease (AD), but is present in other pathological
conditions, including glaucoma (McKinnon, 2003). Although it
is not directly involved in the structural maintenance of the
cytoskeleton, Aβ may play an active role in axonal transport
deficits. Elevations in Aβ protein fibrils and oligomers coincide
with elevated intracellular calcium concentrations (Kawahara
and Kuroda, 2000), and oligomeric Aβ has been associated
with inhibition of fast axonal transport (Morfini et al., 2009).
Evidence of Aβ in animal models of glaucoma as well as in
human glaucomatous eyes (McKinnon, 2003; Ito et al., 2012)
further asserts the necessity of considering the role of such AD
pathophysiological elements in the context of glaucoma.
In the current study, we assessed the relationship between
cytoskeletal changes, axonal transport deficits, and primary
risk factors (i.e., age) in glaucoma. Using a combination
of neuronal tract tracing, immunofluorescence, and advanced
protein quantitation techniques, we examined levels of extremely
hyperphosphorylated (i.e., superphosphorylated) neurofilament
(pNF-H), phosphorylated tau (ptau-231), spectrin breakdown
product (SBDP 145/150; cleaved αII-spectrin), β-tubulin, and
Aβ42 throughout the retinal projection of DBA/2J mice as
a function of age and extent of axonal transport deficits.
Overall, our data support that initial cytoskeletal changes in
the distal retinal projection occur before large-scale anterograde
transport loss and subsequent axon degeneration, emphasizing
the importance of these elements as potential targets for early
intervention in the disease.
METHODS
DBA/2J Mouse Model of Glaucoma
Eighty-three mixed-sex (30 male, 53 female) DBA/2J and
DBA/2J-Gpnmb+ mice of different ages were used for protein
quantification and immunofluorescence studies. The DBA/2J
mouse has two loss of function mutations that produce iris
atrophy, resulting in age-related elevation of IOP and progressive
degeneration of visual structures that mimic human glaucoma
(John et al., 1998; Burroughs et al., 2011). DBA/2J-Gpnmb+
mice (D2G) have the same genetic background as DBA/2J mice;
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however, they express a functioning wild-type Gpnmb+ allele
that prevents development of elevated IOP or glaucomatous
pathology (Howell et al., 2007). For our experimental staging
in the DBA/2J strain, we used 3–5 month old mice (D3-
5) representing pre-glaucomatous ages, 8–10 month old mice
(D8-10) representing early glaucomatous pathology where
anterograde transport deficits and mild axonopathy are evident,
and 12–15 month old mice (D12-15) representing increasing
transport deficits, axonopathy, and RGC soma loss characteristic
of late glaucomatous pathology. Staging of DBA/2J glaucomatous
mice was consistent with previous work published by our lab
as well as others and was based on anterograde and retrograde
transport loss as well as eventual RGC loss in this model (John
et al., 1998; Howell et al., 2007; Buckingham et al., 2008; Crish
et al., 2010; Dengler-Crish et al., 2014; Wilson et al., 2015). For
control comparisons, we used 3–5 and 12–15 month old D2G
mice to represent ages targeted for pre-glaucomatous and late
glaucomatous time points in the DBA/2J strain (G3-5 andG12-15
respectively). Table 1 describes experimental and control group
nomenclature and provides specific sample sizes. All mice were
originally obtained from The Jackson Laboratory (Bar Harbor,
ME, USA) and were housed and aged under the same conditions
in the Comparative Medicine Unit at Northeast Ohio Medical
University. Mice were maintained on a 12-h light/dark cycle
with standard rodent chow available ad libitum. All experimental
procedures were conducted in accordance with the guidelines of
the Northeast OhioMedical University Institutional Animal Care
and Use Committee (IACUC). All protocols for animal use were
approved by this IACUC prior to initiation of the study.
Anterograde Tracing
Anterograde tract tracing methods were used to assay
anterograde transport integrity between each retina to the
corresponding contralateral superior colliculus (Crish et al.,
2010). Mice were anesthetized with 2.5% isoflurane and placed
prone in a stereotaxic device (Stoelting, Wood Dale, IL). Cholera
toxin B-subunit conjugated to Alexa Fluor 488 (CTB) was
injected into the vitreous chamber of both eyes (1.5µl of 0.1%
CTB in sterile physiological saline per eye; Life Technologies:
Grand Island, NY) using a 33-gage needle attached to a 25µl
Hamilton syringe. Mice were then allowed to recover and
were returned to their home cages. Forty-eight hours later,
mice were sacrificed by either transcardial perfusion with
4% paraformaldehyde for immunofluorescence assays or by
decapitation under 5% isoflurane anesthesia to collect fresh
tissue for protein quantitation procedures.
Tissue Collection
Eyes, brain, and ONs were harvested from mice perfused for
immunofluorescence assays; brains were post-fixed overnight
while eyes andONswere post-fixed for 2 h. Tissue was transferred
to 20% sucrose in phosphate buffered saline (PBS) prior to
sectioning. Brains were sectioned coronally through the rostral-
caudal extent of the SC at 50µmon a freezing-slidingmicrotome;
ONs were sliced longitudinally at 20µm. Retinas were dissected
from eyes.
In mice sacrificed for protein quantitation, retina, ONs,
SC, and cerebellum (as a control structure) were collected and
immediately frozen on dry ice, following the microdissection
procedure previously described in Wilson et al. (2015).
Whole-mount SC imaging was done with a Zeiss AxioZoom
V16 epifluorescent microscope equipped with a digital high-
resolution camera (AxioCamMRmRev.3; Zeiss: Jena, Germany).
Under 16.2x magnification, microdissection of the SC was
performed to collect transport-intact (CTB-positive) and
transport-absent (CTB-negative) regions which were analyzed
separately in order to parse out the relationship between
transport outcome and protein levels. Retinas were flattened
and examined to determine success of the tracer injection as
described in Dengler-Crish et al. (2014). Tissue was stored frozen
at−80◦C until use.
Sandwich ELISAs for pNF-H and Aβ42
Enzyme-linked immunosorbent assays (ELISA) were used to
quantify pNF-H (ELISA-pNFH-V1: EnCor Biotechnology Inc.;
Oxfordshire, UK) and Aβ42 (#KMB3441: Life Technologies,
Carlsbad, CA). Frozen tissue samples were homogenized via
sonication (Branson Digital Sonifier; 10% amplitude for two 2-
s pulses) in buffer (for pNF-H: 4 M Urea, 1mM EDTA, 1mM
EGTA, 0.2mM PMSF, with 1X Halt protease and phosphatase
inhibitors; for Aβ42: 5 M Guanidine-HCl in Dubellco’s PBS,
0.2mM PMSF, and 1X Halt protease inhibitor cocktail).
Homogenate volume was approximately 100µl buffer per mg
of tissue. Homogenates were centrifuged at 15,200 × g and 4◦C
for 5 or 20min, for pNF-H and Aβ42 samples, respectively.
Supernatants were decanted into fresh Eppendorf tubes. Samples
were diluted 1:50 with the EnCor protein block for pNF-H assays
or 1:20 in PBS for Aβ42 assays and the assays were carried out
according to the manufacturers’ protocols. Protein standards
were provided in each ELISA kit. Briefly, antibody-coated
microplates were incubated with 100µl of sample, standard, or
background (assay buffer/diluent buffer) at room temperature
(RT) for 2 h. Plates were washed three times with wash buffers
provided in kits, then 100µl of detection antibody was added
to all wells and incubated for 1 h at RT. Plates were washed
3 times and 100µl of HRP-conjugated secondary antibody was
added to all wells and incubated for 1 h. After three washes, 100µl
of 3,3′,5,5′-tetramethylbenzidine (TMB) substrate was added to
every well and incubated at RT for 25–30min. Stop solution
(2N H2SO4) was added and plates were read at 450 nm on a
SpectraMax 340 PC plate reader (Molecular Devices, Sunnyvale,
CA) using SoftMax Pro 5.2 analytical software. Mean absorbance
values were recorded and calculated concentrations were based
on the standard curve.
Tau Multiplex
Phosphorylated tau (ptau-231; phosphorylated at the threonine
231 site) and total tau proteins were measured using magnetic
bead-based neurodegeneration multiplex plates for the Luminex
platform (HND1Mag-39K; EMD Millipore, Billerica MA). Fresh
tissue samples were homogenized via sonication in T-Per buffer
supplemented with Halt protease and phosphatase inhibitors
and centrifuged at 1000 × g for 10min. Supernatants were
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TABLE 1 | Group nomenclature.
Strain Age Group nomenclature Projections analyzed
pNF-H Aβ42 ptau-231 Total tau SBDP β-tubulin
D2G 3–5
D2G*
8 12 4 4 – –
D2G 12–15 8 6 4 4 4 4
DBA/2J 3–5 D3–5 10 14 9 9 4 4
DBA/2J 8–10 D8–10 18 14 6 6
7** 7**
DBA/2J 12–15 D12–15 16 18 6 6
*Single asterisks denotes that both young and old controls were collapsed into a single group, when possible, to simplify analyses.
**Double asterisks denotes that a new combination of ages was used for the SBDP and β-tubulin analyses. An overarching “pathological” group consisting of animals aged 10–12
months was used here.
collected for further analyses; pellets were re-suspended with
50–100µl of additional T-Per buffer and were centrifuged a
final time (1000 × g, 10 min, 4◦C) with supernatants added
to final sample volume. Multiplex analyses were conducted
according to manufacturer’s instructions. In brief, a solution
containing antibody-coupled beads for total tau and ptau-231
were pipetted into a 96-well microplate (25 µl/well). Twenty-
five microliters of assay diluent was then added, followed by
25µl of sample or appropriate standard. Plates were light-
protected and incubated for 16–18 h on an orbital shaker (500–
600 rpm) at 4◦C. Following incubation, plates were washed three
times with manufacturer-provided detergent solution using a
handheld magnet to keep beads in place. Twenty-five microliters
of HRP-conjugated detection antibody was added to all wells and
incubated at RT for 1 h (shaking at 500–600 rpm). Plates were
washed three times as described and 25 µl of Streptavidin-RPE
was added to wells. After a final wash, 100µl of Magpix drive
fluid was added to wells, plates were vigorously shaken for 3min,
and then plates were read on a Magpix Luminex 200. Xponent
software was used to generate a standard curve for each analyte
from which concentrations of unknown samples were calculated.
Automated Capillary-Based Western
Blotting for SBDP and β-Tubulin
Analyses for SBDP and β-tubulin were performed using
Wes, an automated capillary-based Western blotting platform
(ProteinSimple, Santa Clara, CA). Brain samples used for Wes
were selected from DBA/2J mice demonstrating either intact
CTB transport (no visible deficit in the SC) or 0% transport
(no detectable CTB label in the SC). T-Per buffer containing
Halt protease and phosphatase inhibitors was added to samples
(approximately 10 µl per 1 µg of tissue), tissue was then
homogenized via sonication (20% amplitude for two, 2-s pulses),
and brain homogenates were centrifuged at 14,000 rpm for
10min at 4◦C. Wes procedures were performed according to
manufacturer protocol. Briefly, brain or ON homogenate was
diluted to 0.1 µg/µl in 0.1X sample buffer and a fluorescent
master mix (1 µl per 5 µl total volume) was added; the sample
solutions and ladder were then placed in a thermocycler and
heated to 95◦C for 5min and subsequently cooled to 25◦C.
The samples, blocking reagent, wash buffer, primary antibodies,
HRP-conjugated secondary antibodies, chemiluminescent
substrate, and separation/stacking matrices were dispensed into
a pre-filled microplate (ProteinSimple, PS-PP03). After plate
loading, immunodetection was fully automated using default
instrument settings for size-based assays. Primary antibodies
used were SBDP (mouse, 1:20; Santa Cruz, Dallas, TX) and
β-tubulin (rabbit, 1:200: Covance/BioLegend, San Diego, CA).
GAPDH (1:100: Sigma-Aldrich, St. Louis, MO) was used as
a loading control. All antibodies were diluted with antibody
diluent (ProteinSimple, 042-195). Resulting chemiluminescent
signals were quantitated and analyzed with Compass software
(ProteinSimple v2.5). Protein densitometry was calculated by
dividing the area under the curve of each protein of interest by
area under the curve of the loading control (GAPDH).
Bicinchoninic Acid Assay for Total Protein
Total protein content was assessed in tissue samples using the
Pierce Bicinchoninic Acid (BCA) assay kit (Thermo Fisher;
#23227) and individual protein levels were normalized to total
protein content within tissue samples. Samples for pNF-H were
diluted to a urea concentration compatible with the assay
(<3mM).
Calculating Percent Intact Transport
Whole-mount SC were imaged with the Zeiss AxioZoom
microscope to capture the full extent of the dorsal surface
of the SC. Captured images were imported into ImagePro
Premier (Media Cybernetics; Rockville, MD) software where
areas containing CTB signal were defined within the total SC
area. To quantify percent intact transport of each SC, the area
of intact CTB transport was divided by the total collicular area
(Wilson et al., 2015).
Immunofluorescence
Sections from fixed retina, brain, and longitudinal ON were
blocked with 5% normal donkey serum and 0.1% Triton-X 100
in PBS for 2 h and then incubated for 48 h at 4◦C with the
primary antibody cocktail (diluted in 3% serum, 0.1% Triton in
PBS). Primary antibodies used consisted of the following: mouse
anti-SMI-310 (superphosphorylated NF-H 1:1000; AbCam,
Cambridge, MA), rabbit anti-tau p231 (1:400; Life Technologies),
or rabbit anti-tubulin β-III (1:1000; BioLegend), and goat
anti-Brn3a (1:400; Santa Cruz) for identification of retinal
ganglion cell bodies. Staining for “superphosphorylated” NF
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is distinguished from the more typical “hyperphosphorylated”
phosphoisoforms seen with other pNF antibodies (e.g., SMI-
31, SMI-34, RT97) in that the former represents the highest
level of phosphorylation of all the antibody-detected NF
phosphoisoforms, and is typically only found in a subset of
axons in normal tissue. Assessment of superphosphorylated NF
allows us to identify pathological changes in the axon that
might be masked by the relatively high expression of other NF
phosphoisoforms in normal tissue. Following primary antibody
incubation, tissue was washed in PBS and Alexa Fluor secondary
antibodies (Jackson Immunoresearch Laboratories, West Grove,
PA) against mouse, rabbit, and/or goat (diluted 1:250 in PBS
containing 0.1% Triton X-100 and 1% normal donkey serum)
were then added and sections were incubated for 2 h at room
temperature. Tissue was then washed with PBS, mounted onto
slides and cover-slipped with Fluoromount-G (Southern Biotech,
Birmingham, AL) prior to visualization.
Semi-Thin Optic Nerve Embedding,
Sectioning, and Immunofluorescence
Perfusion-fixed ONs were immediately placed in 1%
glutaraldehyde for 3 h and were then washed in buffer (3.5%
sucrose/50mM glycine in 0.01 M PBS) for 10min. Tissue was
dehydrated using cold 70% ethanol followed by 95% ethanol,
and 100% ethanol each for 5min. Tissue was then placed in a
(1:1) mixture of LR white resin (#62662; Sigma-Aldrich) and
100% ethanol for 5min. After removal from mixture on day 2,
tissue was placed in fresh LR white twice, for 5min each, prior to
overnight incubation in LR white, at 4◦C. On day 3, tissue was
added to gelatin capsules (#7114, Electron Microscopy Sciences,
Hatfield, PA) filled with LR white, covered, and placed in an oven
at 50◦C for overnight infiltration.
Using a Leica UC6 ultramicrotome (Buffalo Grove, IL)
equipped with a Diatome diamond knife (Ultra 45, 3.0 mm),
1 µm cross-sections were collected and mounted onto subbed
glass slides. Tissue was blocked with 5% normal donkey serum
and 0.1% Triton-X 100 in PBS for 2 h. Tissue incubated for
48 h at room temperature in primary antibody solution (3%
serum, 0.1% Triton in PBS) consisting of anti-β-tubulin III
(1:50; BioLegend) and anti-SMI310 (1:400; AbCam). Following
primary antibody incubation, tissue was washed in PBS (10min,
x3) before secondary antibody incubation using Alexa Fluor
secondary antibodies (Jackson Immunoresearch Laboratories)
against mouse, rabbit, and/or goat (diluted 1:200 in PBS
containing 0.1% Triton X-100 and 1% normal donkey serum)
overnight at room temperature. Tissue was then washed with PBS
before slides were cover slipped using Fluoromount-G mounting
media.
Immunofluorescence Imagining
Immunofluorescence imaging of retina, SC, and cross-section
ON was completed using a Zeiss Axio Imager M2 epifluorescent
microscope outfitted with an Apotome.2 for obtaining optically
sectioned images, digital high resolution camera (AxioCamMRm
Rev.3), and motorized Z and X-Y stage (Zeiss, Jena, Germany).
Longitudinal ON were imaged using the Zeiss AxioZoom V16
epifluorescent microscope.
Tau-Dynactin Co-immunoprecipitation
To test the effect of tau hyperphosphorylation on its affinity
for the retrograde motor component, dynactin, we performed
co-immunoprecipitation comparing native tau (that exhibits
a low level of phosphorylation) and tau hyperphosphorylated
by pretreatment with glycogen synthase kinase 3β (GSK-3β;
a kinase that has tau as one of its major substrates). In a
1.5 ml Eppendorf tube, 30 µl of Dynabeads-G (ThermoFisher,
#10003D) was bound with 10 µl of antibody against dynactin-
2 (AbCam, #EPR5095), which was then allowed to bind 5µg
recombinant dynactin-2 (0.5 µg/µl; OriGene Technologies Inc.,
Rockville, MD; #TP314771). The tubes were rotated for 20min
at RT to ensure thorough mixing. Five micrograms of human
tau-412 isoform (1µg/µl; rPeptide, LLC, Bogart GA), was treated
with either GSK-3β, lambda phosphatase, or PBS and incubated
at RT for 30min. The tau solutions were then mixed with
dynactin-bound Dynabeads and allowed to rotate for 20min.
Fifty microliters of Laemmli buffer was added to each reaction
and tubes were heated at 70◦C for 10min. Forty microliters of
each solution was used to performWestern blots which were run
on 4–15% Mini-Protean TGX precast gels (Bio-Rad, Hercules,
CA; #4561083SEDU) and Immun-Blot PVDF membranes (Bio-
Rad; #1620177). Membranes were probed with an antibody
against pan-tau (anti-Tau-5; AbCam #ab80579) to determine
relative amounts of total tau pulled out in each reaction context.
Blots were stripped (RestoreTM Western Blot Stripping Buffer;
ThermoFisher; #21059) and probed with a phospho-specific
antibody (phospho-(Ser/Thr) Phe Antibody; Cell Signaling,
Anvers, MA; #9631) to confirm differences in phosphorylation
state. Control blots were run using either Dynabeads-only (30
µl), pure dynactin, or native tau protein (1 µg).
Statistical Analyses
IBM SPSS Statistics 22 (IBM Corp: Armonk, NY, USA) was used
for all statistical analyses. To justify pooling D2G results into a
unitary control group, two-tailed, independent samples student
t-tests were performed to confirm similarity of results between
young (3–5 months.) and old (12–15 months.) D2G control
animals. Assessments regarding whether pooling was applicable
were made separately for each protein (pNF-H, ptau, total tau,
and Aβ42) and tissue type (retina, ON, SC, and cerebellum).
Independent samples t-tests were performed to determine any
initial sex differences in protein quantification measurements
within each strain/age group of mice prior to assessment of
our overall hypotheses. To test our overall hypotheses, we
conducted one-way analyses of variance (ANOVA) using protein
concentration (pNF-H, ptau, total tau, and Aβ42) per anatomical
region (retina, ON, SC and cerebellum control) as the dependent
variable and strain/age group as the independent variable.
Bonferroni-corrected post hoc comparisons were performed to
elucidate specific group differences. For other analyses, we used
transport outcome as our independent variable to determine
whether proteins levels in each region differed in transport-
intact (CTB-positive) vs. transport-deficient (CTB-negative)
projections. Since the distribution of projections with intact
transport was variable in the D8-10 DBA/2J group (53% intact)
and skewed substantially toward loss in the D12-15 group
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(15% intact), we pooled data across these two age groups to
have sufficient cases to support each level of our dichotomous
transport-intact/deficient variable for analysis. In addition to
this dichotomous transport variable, we also used a continuous
variable of “percent intact transport” for our correlational
analyses.
RESULTS
D2G Mice Show No Differences in Protein
Concentrations Based on Age
To assess whether age-related differences in cytoskeletal
components occur independent of strain, we compared pNF-H
protein levels in retina, ON, SC, and cerebellum (control
structure) between young (3–5 months.) and old (12–15
months.) D2G using independent samples t-tests. No significant
differences in pNF-H levels were shown between young and
old D2G for any structure (refer to Table 2). These results
were recapitulated in analyses of Aβ and tau proteins as well.
Therefore, young and old D2G were pooled into a single control
group for all subsequent analyses. No significant sex differences
were observed within either D2G age group.
pNF-H Levels in DBA/2J Mice are Elevated
in an Age and Transport Dependent
Manner
DBA/2J Mice Show Early pNF-H Elevations in SC and
Late Increases in the Retina, with Transitional
Changes Occurring in ON
Figure 1 depicts results for pNF-H analyses. As shown in
Figure 1A, pNF-H protein concentration differed between
strains in the retina [F (3, 55) = 3.116, p = 0.034], ON [F
(3, 52) = 17.206, p < 0.001], and SC [F (3, 50) = 3.653, p =
0.019] with no differences in cerebellar control tissue (Table 2).
TABLE 2 | Young and aged D2G comparisons.
Protein Structure t Mean Difference p-value
pNF-H Retina 0.316 0.001547 0.757
ON 2.28 0.063000 0.063
SC 0.558 0.011460 0.578
Cerebellum −0.073 0.001700 0.949
Aβ42 Retina 0.688 0.749250 0.501
ON 2.016 2.590410 0.075
SC 0.424 0.753093 0.681
Cerebellum 0.237 1.493809 0.834
Ptau-231 Retina −0.64 0.002750 0.568
ON 0.873 0.024179 0.447
SC −0.826 0.001414 0.561
Total tau Retina −0.534 0.000016 0.631
ON 1.083 0.000459 0.358
SC −0.983 0.000000 0.506
An approximate 5-fold increase in collicular pNF-H was seen
in the 8–10 month DBA/2J group (p = 0.020) compared
to controls. Retinal pNF-H levels did not significantly differ
between groups until DBA/2J mice were 12–15 months of age,
whereby pNF-H levels were increased by nearly 5-fold in 12–
15 month DBA/2Js compared to controls (p = 0.033). pNF-
H results in the ON showed a transitional pattern of results,
with D8-10 mice displaying significantly higher pNF-H levels—
more than double—in comparison to D2G controls and D3-
5 (p = 0.003) and D12-15 (p < 0.01) mice. Further, we saw
elevations of pNF-H in the most superficial SC between groups
(Figure 1A). Following the pattern of ON NF levels, we see
an increase of pNF in D8-10 followed with a reduction in the
oldest age group. Figure 1B shows immunofluorescent labeling
of superphosphorylated NF-H (SMI-310) in retina and ON.
Retinas show low levels of pNF and ptau in the control retina with
the D8 retina showing greatly increased levels of pNF and ptau,
with both proteins being aberrantly localized in the RGC somata
(labeled with Brn3a), a sign of pathology. Immunofluorescence
staining in our semithin cross-sections of ON is also consistent
with results from the protein quantification. We found low levels
of pNF-H in aged control mice with very robust staining evident
in a D9 ON. This staining is greatly reduced in the D13 ON,
likely due to axon loss, as evidenced by the massive reduction
in β-tubulin seen in the same section. No sex differences were
observed within retina, ON, or SC of any DBA/2J age group.
pNF-H Levels in Retina and SC Vary Based on
Transport Outcome in DBA/2J Mice
Collicular tissue was microdissected to separate CTB+ from
CTB- areas, each area was run separately. For retina, total CTB+
area of corresponding collicular lobe was used for classification.
We contrasted pNF-H levels in retinal projections taken from
mice with deficient (0–20%) anterograde transport (CTB-) in the
SC with projections taken from SC displaying full tracer coverage
(CTB+) and these data are presented in Figure 2. Only DBA/2J
mice in the D8-10 and D12-15 groups displayed transport deficits
(as anticipated based on the established trajectory of transport
loss in this model) with only 15% of D12-15 colliculi exhibiting
any detectable CTB label whatsoever. To maximize detection of
differences in pNF-H levels as a function of transport outcome,
we pooled data across the two pathologically-aged DBA/2J
groups (D8-10 and D12-15). Significant elevations of pNF-H
were indicated in both SC [F (1, 53) = 8.288, p = 0.006] and
retina [F (1, 59) = 5.816, p = 0.019] of transport deficient (CTB-)
projections compared to intact (CTB+) projections (Figure 1A).
There were no differences inONor cerebellum levels (not shown)
of pNF-H as a function of transport outcome. For both SC and
retina, the percent of intact transport was negatively correlated
with pNF-H levels indicating that pNF-H levels increased as
a function of transport deficit magnitude in these structures
(SC: Pearson r2 = −0.358; retina: Pearson r2 = −0.317, p <
0.05 in both cases). pNF-H levels in the ON did not show this
same relationship to transport deficit magnitude. There were no
observed differences in transport outcome to the SC based on
mouse sex.
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FIGURE 1 | Early elevations in pNF-H observed in distal RGC projection with effects of age and transport outcome. (A) Quantification of pNF-H by ELISA
in retina, optic nerve (ON), and superior colliculus (SC). DBA/2J retinal pNF-H levels show trending increase with age peaking at 12–15 months at which point, is
significantly elevated compared to the D2G controls. In the ON, pNF-H levels were highest at 8–10 months. in the DBA/2J mice but returned to levels similar to the
D2G controls at 12–15 months. In the SC, pNF-H levels remained significantly elevated in the D8-10 group compared to controls. (B) (Top) Immunofluorescence of
cytoskeletal markers, SMI-310 (specific for superphosphorylated, pNF-H) and the RGC marker Brn3a in the retina of an 8-mo. DBA/2J (D8) and D2G control.
Micrographs show visibly increased pNF-H and somatic/axonal ptau-231 staining in the D8 retina. The D2G pNF-H labeling is typical of mature, non-pathological
axons within the retina. (Bottom) Semithin (1 µm) cross-sections taken from 8-months. DBA/2J (D8), 13-months. DBA/2J (D13), and 17-months. D2G (G17) control
ON immuno-stained for β-tubulin (β-TUB) and pNF-H. A significant increase in pNF-H is observed in the D8 ON compared to G17 control. In the D13, pNF-H in the
ON is nearly absent corresponding to the prominent loss of axonal structure indicative by the reduction in β-TUB. Error bars depict SEM. Asterisk indicates significant
statistical difference (p < 0.05).
Frontiers in Neuroscience | www.frontiersin.org 7 November 2016 | Volume 10 | Article 494
Wilson et al. Early Cytoskeletal Modifications in Glaucoma
FIGURE 2 | Transport-dependent elevations in pNF-H observed in retina and SC of DBA/2J mice. (A) (Left) Photomicrograph from the dorsal surface of a
whole-mount pathological SC in which the cortex has been removed and cholera toxin-B (CTB) labeling shows sectorial loss in the left (top) collicular lobe and
complete loss in the right (bottom) lobe. Abbreviations: IC, inferior colliculus; PT, pre-tectum; LGN, lateral geniculate nucleus; SC, superior colliculus. The dotted lines
demarcate areas absent of CTB indicating axonal transport deficit (CTB-). (Right) ELISA quantification of pNF-H in retina, optic nerve (ON), and SC. The transport
status of retina and ON were determined by whether or not the SC was CTB+ (>90% CTB-label for partially transporting projections) or CTB- (<10% CTB-label for
partially transporting projections). Levels of pNF-H were significantly elevated nearly 2-fold in both retina and SC of CTB- projections compared to CTB+ projections.
Asterisks indicate significant statistical differences (p < 0.05). Error bars depict SEM. (B) Top panel shows immunofluorescence of the SC, comparing 7-months. (D7),
and 11-months. (D11) DBA/2J with and without CTB transport. Visibly increased pNF-H is shown in CTB- D11 SC. Bottom panel illustrates an age-dependent
increase in pNF-H staining in the LGN (the visual thalamus) of 6, 11, and 14-month DBA/2J mice.
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Phosphorylated Tau Shows
Age-Dependent Changes in Retina and ON
Age-Dependent Elevations in Ptau in DBA/2J Mouse
SC and Retina
Concentrations of ptau-231 differed as a function of DBA/2J age
group in retina [F (3, 22) = 3.850, p = 0.026] and SC [F (3, 16) =
7.209, p = 0.004] but not in ON or control cerebellar tissue.
Specifically, collicular ptau-231 was elevated by more than 4-fold
in the youngest DBA/2J group (D3-5) compared to D2G controls
(p= 0.007) and D12-15 mice (p= 0.011) (Figure 3). In contrast,
retinal levels of ptau-231 were significantly increased about 3-
fold in the D12-15 group compared to D2G controls (ptau-231;
p =.022) and displayed a stepwise pattern of age-related increase
among DBA/2J mice (Figure 3A). As shown in Figure 2B, there
was a notable elevation in ptau-231 immunofluorescent labeling
in the somata and axons of an 8-month old DBA/2J retina
compared to retina from an 11-month old D2G control, despite
no differences in the distribution of the RGC marker Brn3a
between retina of these mice. Although differences in ptau-
231 protein levels between groups were not detected in of
ON homogenates, immunofluorescent ptau labeling in fixed
longitudinal ON sections of 14-month old DBA/2J showed an
intriguing distal-to-proximal distribution. Ptau-231 label was
obvious in myelinated proximal ON but was sparse in the distal
portion of the nerve (Figure 3C), and this pattern was observed
in three cases of D14 ON and not in any other age groups.
Relationships between transport deficits and ptau-231 protein
levels could not be determined due to high variability in tau
protein concentrations and small sample sizes of transport-intact
mice in the oldest DBA/2J age groups. No sex differences were
observed within retina or SC of any DBA/2J age group.
Tau-Dynactin Co-Immunoprecipitation
To further explore the age-related distal-to-proximal distribution
of ptau in the DBA/2J retinal projection, we conducted
a co-immunoprecipitation assay for differences in binding
affinity of different tau phosphoisoforms with dynactin-2,
the link between the retrograde molecular motor dynein
and cytoskeletal elements. Results indicated that more tau
protein was pulled down by the dynactin protein after GSK-
3β-mediated phosphorylation compared to native conditions
or phosphatase pre-treatment, as observed by Western blot
(Figure 3C). Dynabead-only, tau, or dynactin alone conditions
showed little if any non-specific binding. Blots were stripped and
probed with a phospho-specific antibody to confirm differences
in phosphorylation state (not shown).
Elevations in SBDP Observed Early in ON
and SC of DBA/2J Mice
Comparisons of spectrin breakdown product (SBDP) protein
levels were only performed between groups of D2G, D3-5, and
D10-12 DBA/2J mice with this oldest group exhibiting a bimodal
distribution in terms of transport outcome (CTB+/CTB-). SBDP
levels varied significantly between these groups in the ON [F
(3, 13) = 32.36, p < 0.01] and SC [F (3, 13) = 4.718, p = 0.027].
Interestingly, D3-5 DBA/2J mice demonstrated significantly
elevated SBDP in ON compared to all other groups (p < 0.01
for all comparisons; Figure 4A), a difference of more than 10-
fold. These young DBA/2J mice also expressed collicular levels
of SBDP that were more than double the levels detected in D2G
controls (p < 0.05; Figure 4B). As expected based on this result,
SBDP protein levels did not differ as a function of transport
outcome in the D10-12 group exhibiting either fully intact or
completely absent transport to individual SC. No sex differences
were observed within ON or SC of any DBA/2J age group.
Decreased β-Tubulin in
Pathologically-Aged DBA/2J Mice with
Disrupted Transport
To determine whether lower levels of SBDP observed in ON and
SC of 10–12 month old DBA/2J mice were potentially due to an
overall loss or disorganization of structure in aged projections,
we quantified β-tubulin (a major structural component of
microtubules) in these structures. In 10–12 months old DBA/2J
mice, β-tubulin was significantly decreased within the ON
of transport deficient (CTB-) projections relative to transport
intact (CTB+) projections [F (1, 11) = 9.11, p = 0.01], and
transport-deficient D10-12 projections also had lower levels of β-
tubulin levels compared to D2G projections [F (3, 11) = 5.053,
p = 0.030] (Figure 4A). Immunofluorescent staining in the
ON also reflected decreased β-tubulin and CTB label in 11-
month old DBA/2J tissue compared to 6-month old DBA/2J
ON (Figure 1B). No significant differences in collicular β-tubulin
levels were detected between any groups (Figure 4B); however,
β-tubulin levels in this region showed trends similar to those
observed in the ON. No sex differences were observed within ON
or SC of any DBA/2J age group.
Elevations in Aβ42 Levels in DBA/2J
Retinal Aβ42 Levels Are Elevated in all DBA/2J Mice
Regardless of Age, but Show Age-Dependent
Increases at the Level of the SC
Retinal and collicular Aβ42 levels varied as a function of strain,
age, and location [retina: F (3, 61) = 5.886, p< 0.01; SC: F (3, 38) =
7.760, p < 0.01]. Retinal Aβ42 was elevated in all age groups of
DBA/2J mice, by three to four times, relative to D2G controls
(p ≤ 0.010 in all analyses; Figure 5A, top). Collicular Aβ42 was
significantly elevated in D8–10 and D12–15 mice by more than
double control levels, but not in the young D3–5 group (p< 0.05
in both cases; Figure 5B, top). In DBA/2J SC, Aβ42 was highest
in the D8–10 group, although statistically these Aβ42 values only
differed from the D3–5 group (p= 0.03). Aβ42 levels in cerebellar
tissue did not differ by age or strain. No sex differences were
observed within retina or SC of any DBA/2J age group.
Aβ42 Levels Are Elevated in DBA/2J SC as a Function
of Transport Loss
As illustrated in Figure 5B (bottom), Aβ42levels were increased
in SC of transport-deficient (CTB-) projections relative to
transport-intact (CTB+) projections of DBA/2J mice (collapsed
across D8–10 and D12–15 groups) [F (1,41) = 8.044, p = 0.007].
No transport-related differences were found in retina (Figure 5A,
bottom) or ON samples (not shown).
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FIGURE 3 | Phosphorylated tau (ptau-231) is elevated early in the distal projection and is observed to translocate to the retina in pathologically-aged
animals. (A) Multiplex quantification of ptau-231 in DBA/2J mice shows an age-dependent decrease of ptau in SC with an age-dependent increase in retinal ptau. In
the SC, ptau-231 is significantly higher in the D3-5 group compared to D12-15 and D2G control group levels. In retina, however, D12-15 ptau-231 levels are
significantly higher than D2G controls. Ptau levels in ON samples did not differ between groups. (B) Immunofluorescence for ptau-231 in 10-months. DBA/2J ON
shows evidence of preferential accumulation of ptau-231 in the proximal portion compared to the distal portion of the nerve. (C) An example of
co-immunoprecipitation data comparing native and hyperphosphorylated tau via reaction with GSK-3 suggests an increased affinity of phosphorylated tau for the
retrograde motor component, dynactin-2. This is qualitatively illustrated by the increased optical density of Tau-5 (a marker for pan-tau) in the second lane
representing hyperphosphorylated tau (GSK-3+Tau-412), compared to the first lane which contained only native tau. The tau band shown here corresponds to a
molecular weight of approximately 43.5 kDa corresponding to the GSK-3 phosphorylation site, pS396/404. Asterisk indicates that groups are significantly different
from bracketed comparison (p < 0.05). Error bars depict SEM.
DISCUSSION
Pathological phosphorylation and cleavage of cytoskeletal
elements are commonly implicated in chronic neurodegenerative
conditions, including glaucoma (Lee et al., 2000; Colucci-
D’Amato et al., 2003; Knobloch and Mansuy, 2008; Chidlow
et al., 2011). Specifically, roles for pNF-H, ptau, spectrin, β-
tubulin, and the pathological protein Aβ42 in the development,
progression, and even classification and diagnosis of degenerative
conditions have been prominent in both the clinical and basic
research literature. However, the present experiments are the first
to quantify this specific subset of proteins throughout the entire
retinal projection of a glaucomatous mouse model; likewise,
this study is the first to associate protein quantification with
measures of axonal transport from the retina to its primary
projection target in mouse, the SC. Our data (summarized
in Figure 6) indicate that post-translational phosphorylation
of neurofilament heavy-chain and tau occurs with age in
DBA/2J mice. Spectrin breakdown in ON and SC precedes
these effects, and early elevation of retinal Aβ42 was evident
in the youngest, pre-pathological age group of DBA/2J mice
studied. Consequently, elevations in these proteins occur prior
to anterograde transport loss in this well-characterized glaucoma
model. When the temporal context of these molecular change
are considered, it is plausible that early spectrin cleavage and
Aβ42 accumulation may perpetuate the sequence of degenerative
events by facilitating aberrant cytoskeletal phosphorylation and
thus, provoking disease progression (Dixit et al., 2008).
Microtubules are the substrate along which motor proteins
carry cargo within axons. Therefore, disruption of microtubule
organization inhibits axonal transport and, depending on the
location and severity of the disruption, can trigger various
destruction programs ranging from distal axonopathy to
apoptosis (Cuchillo-Ibanez et al., 2008; Song et al., 2013;
Zempel and Mandelkow, 2015). Relevant to our findings,
abnormal microtubule distribution has been observed following
laser coagulation-induced ocular hypertension in rats (Huang
et al., 2011). Pharmacological disruption of microtubules with
nocodazole treatment indicated that microtubule disruption is
an early clinical event that occurs prior to decreased retinal
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FIGURE 4 | Spectrin breakdown product (SBDP) 145/150 is elevated in young DBA/2J ON and SC while β-tubulin is decreased in a
transport-dependent manner in pathologically-aged ON. (A) Chemiluminescence-based quantification using ProteinSimple Wes technology illustrates
significantly higher levels of SBDP(145/150) within ON of D3-5 mice compared to all other groups, with no differences seen in pathologically-aged (10–12 months.)
DBA/2J mice regardless of transport outcome. Bar graph (top) shows SBDP145/150 and β-tubulin normalized to GAPDH (a housekeeping gene marker), while
corresponding examples of automated western output are shown below for ON. Importantly, a significant decrease in β-tubulin was observed in pathologically-aged
ON associated with zero anterograde transport to the corresponding SC compared to controls and D10-12 mice with intact transport. (B) A significant elevation in
SBDP chemiluminescence was observed in D3-5 SC compared to D2G controls (B), with no differences in collicular β-tubulin elucidated. Bar graph (top) shows
SBDP145/150 and β-tubulin normalized to GAPDH, while corresponding examples of automated western output are shown below for SC. (Refer back to Figure 1 to
see β-tubulin loss using immunofluorescence.) Error bars depict SEM. Asterisk indicates that groups are significantly different from bracketed comparison (p < 0.05)
nerve fiber thickness (Lim and Danias, 2012). Microtubules
require a vast network of stabilizing, support, and adaptor
proteins to maintain their functional and structured matrix
(Ahlijanian et al., 2000; Roy et al., 2005). Neurofilaments, the
most abundant component of the mature axonal cytoskeleton,
aid in organization and stabilization of the microtubule matrix
and other cytoskeletal elements. Phosphorylation of NF-H
controls axon caliber (Petzold et al., 2008; Cooper et al., 2016),
and hyper- or super-phosphorylation of neurofilament can slow
its transport, leading it to accumulate and form aggregates that
ultimately block transport (Nixon, 1994; Elder et al., 1998a,b;
Julien and Mushynski, 1998; Jung and Shea, 1999, 2004),
leading to eventual axon loss (Ackerley et al., 2003; Petzold
et al., 2008; Lépinoux-Chambaud and Eyer, 2013). We showed
that phosphorylated NF-H is significantly elevated in the SC
of DBA/2J mice early (8–10 months) in the progression of
glaucomatous pathology, decreasing only when glaucomatous
pathology advances (12–15 months). Consequently, we also
observed decreased β-tubulin in the ON (and to lesser extent in
the SC) of transport-deficient 10–12 month DBA/2J projections
compared to projections with intact transport—a finding that
suggests loss of microtubule and cellular structure within the
ON and SC as degeneration progresses (Schlamp et al., 2006;
Crish et al., 2010; Adalbert and Coleman, 2012). Supporting this,
our data showed increased pNF-H in the SC and retina of mice
with transport deficits compared to mice with intact transport.
Phosphorylation of neurofilaments decreases their affinity for
tubulin, causing abnormal bundling and disorganization of the
microtubule array (Buée et al., 2000; Jung et al., 2005; Zempel
and Mandelkow, 2015). Therefore, elevation of pNF could be a
driving force for transport loss.
Hyperphosphorylation of the microtubule-associated protein
tau–a pathological hallmark of Alzheimer’s disease (Iqbal et al.,
2016)– promotes abnormal translocation and accumulation of
tau in the soma and aberrant assembly of microtubules, driving
axonal transport deficits and other neurodegenerative effects
(Majid et al., 2014; Morfini et al., 2016). While tauopathy
likely plays a mechanistic role in glaucoma, evidence of tau
phosphorylation and translocation in a glaucoma model has
only recently been uncovered (Chiasseu et al., 2016). The data
from our study show: (1) an age-dependent increase in retinal
ptau and (2) a large decrease in collicular ptau of glaucomatous
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FIGURE 5 | Amyloid-β42 elevations provide an early retinal marker of pathology and are later observed in the distal projection. (A) Retinal Aβ42 was
elevated in all DBA/2J age groups compared to controls (left), with no transport-dependent effects observed (right). (B) However, collicular elevations appeared later,
with 8–10 and 12–15 month DBA/2J SC having significantly elevated levels compared to controls; a significant difference was also observed between 3–5 and 8–10
month DBA/2Js (left). Levels of Aβ42 were significantly elevated in SC lacking intact transport (CTB-) compared to transport-intact (CTB+) SC (right). Error bars
indicate SEM. Asterisk indicates that groups are significantly different from bracketed comparison (p < 0.05).
DBA/2J animals. Supporting this, we found distal-to-proximal
increases in ptau immunofluorescence in the ON of DBA/2J
mice, indicating retrograde translocation of tau in glaucoma
(Buée et al., 2000; Dixit et al., 2008). Additionally, we showed
increased tau phosphorylation (at the threonine-231 residue)
in the SC of our pre-pathological 3–5 months. DBA/2J mice—
an early effect that preceded significant ptau accumulations
in retina. These data suggest that tau translocation from the
axon into the somatodendritic compartments occurs as tau
becomes increasingly phosphorylated. While the mechanism of
this translocation is unknown, it is possible that phosphorylation
not only changes tau’s affinity for microtubules (Johnson
and Stoothoff, 2004) but also increases its affinity for the
retrograde motor complex. Supporting this, we demonstrated
that phosphorylation of tau increases its affinity for dynactin,
a component of the retrograde motor complex that links the
molecular motor dynein with its cargo (recall Figure 3C).
Calpain-mediated cleavage of α-II spectrin, has been
implicated in secondary neurodegenerative processes (such as
those resulting from traumatic brain injury; Yan and Jeromin,
2012) and serves as another indicator of axonal injury and
pathology. Cleaved α-II spectrin has been found in varicosities
and end bulb swellings (Uryu et al., 2007) and is shown
to be upregulated in the retina of rodent glaucoma models
with elevated IOP (Huang et al., 2010). Spectrin organizes the
subaxolemmal actin scaffold that, among other functions, confers
strength to axons (Xu et al., 2013), enabling it to resist mechanical
stresses (Elson, 1988; Zhou et al., 1999; Jung et al., 2005; Xu et al.,
2013). While we were unable to detect SBDP in any DBA/2J or
control retina (in contrast to previous findings by Huang et al.
(2010) who found elevated SBDP in an experimentally-induced
ocular hypertension model), we did observe high levels of
calpain-mediated spectrin breakdown product in the ON and
SC of our pre-pathological, young DBA/2J mice. This result was
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FIGURE 6 | Timeline summary of protein pathology within the DBA/2J
retinal projection. A summary schematic of changes in protein levels over
disease progression (pre-glaucomatous, early, and late glaucomatous ages), in
the DBA/2J mouse model, for each tissue type analyzed (retina, ON, SC) is
shown here. The x-axis corresponds to time while the y-axis corresponds to
general protein levels. Each colored line corresponds to a specific protein: dark
blue corresponds to pNF-H, red corresponds to Aβ42, light blue corresponds
to SBDP, green corresponds to ptau-231, dotted purple corresponds to
β-tubulin. Increased/decreased slope of each line indicates
increased/decreased concentrations of each specific protein over time.
somewhat unexpected, as elevated IOP, transport deficits, and
axon loss are not typically present in DBA/2J at 3–5 months.
Hence, pre-degenerative, post-translational modifications and
breakdown of cytoskeletal elements in DBA/2J mice may make
their RGC axons vulnerable to glaucomatous neurodegeneration
once IOP increases at later ages (Inman et al., 2006).
Elevations in Aβ42 fragments often accompany elevated SBDP
and the pathological phosphorylation of tau and NF-H in
neurodegeneration (Johnson et al., 2016). Aβ42 protein is also
implicated in axon transport deficits and axonopathy (Stokin
et al., 2005; Chidlow et al., 2011), as well as in response to IOP
elevation (Ito et al., 2012). We observed elevated levels of Aβ42 in
the retina of our youngest DBA/2J mice, suggesting this increase
occurs prior to IOP elevation. Levels of Aβ42 remained elevated
in the retina throughout the stages of pathological progression
in DBA/2J, and increased in the oldest DBA/2J age group SC.
While Aβ42 is not a cytoskeletal protein, it activates kinases such
as GSK-3β which phosphorylate NF-H and tau (Muyllaert et al.,
2008; Martin et al., 2011a,b), potentially conferring susceptibility
to axon pathology.
The interplay between early, proximal elevations in Aβ
and post-translational modification of cytoskeletal spectrin and
neurofilament proteins may be partly explained by the calcium
hypothesis of neurodegeneration (Chidlow et al., 2011; Crish and
Calkins, 2011). Elevated intracellular calcium, partially promoted
by Aβ-mediated increases in Ca2+ conductance (Kawahara and
Kuroda, 2000) modulates subsequent calpain activation. Ca2+-
mediated calpain activation leads to specific cleavage of structural
proteins such as neurofilament and spectrin (Crish and Calkins,
2011). This is supported by our observations of elevated calpain-
mediated SBDP and Aβ42 in young, pre-glaucomatous DBA/2J
mice. As these pre-pathological mice do not exhibit elevated
IOP at this early stage, these findings suggest that factors other
than IOP may cause individuals to be predisposed to developing
glaucoma (e.g., subtle changes in kinase activity, excitotoxic
stress, or Aβ42 load). Recent findings showing early increases
in neuroinflammation and oxidative stress are germane here.
Neuroinflammation is the earliest change reported in models
of glaucoma, often occurring well before neurodegeneration
(Wax and Tezel, 2009; Bosco et al., 2011; Howell et al., 2011;
Wilson et al., 2015; Hines-Beard et al., 2016). Neuroinflammation
can, directly or indirectly, increase the activity of a number
of kinases responsible for the phosphorylation of NF and tau
in chronic neurodegenerations (For example, CDK-5: Kitazawa
et al., 2005;Weston and Davis, 2007; Noda et al., 2014). Oxidative
stress is also seen in glaucoma and other neurodegenerations
(Chrysostomou et al., 2013; Inman et al., 2013; Burté et al., 2014;
Kim et al., 2015; Yang et al., 2016) and reactive oxygen species
such as peroxynitrate activate kinases including GSK-3β and
p38 that modify tau and other proteins (Zhang et al., 2006). In
addition, accumulation of Aβ42 and tau have been shown to lead
to mitochondrial dysfunction and generation of reactive oxygen
species (Luque-Contreras et al., 2014), effectively perpetuating
the cycle of pathological phosphorylation and diminished axonal
stability and function.
Conclusions
In conclusion, data from the DBA/2J model of glaucoma
demonstrate that increased phosphorylation of cytoskeletal
proteins such as neurofilament-heavy and tau occurs with
age and pathology within the RGC projection. However, the
relationship is non-monotonic and overall loss of axonal
structure with advanced pathology contributes to decreases in
protein concentration at late glaucomatous ages. Although the
presumptive, initial stressor (elevated IOP) occurs proximally
at the optic nerve head, early manifestations of pathologies can
occur distally, as previously reported (Conforti et al., 2007; Crish
et al., 2010; Crish and Calkins, 2011) and are not isolated to
the eye and retina (Parrish, 2003; Ito et al., 2012). Additionally,
our data describing early, pre-degenerative elevations in Aβ42
and SBDP, have suggested that there are factors other than
elevated IOP perpetuating glaucomatous neurodegeneration or
predisposing RGC populations to respond adversely to high IOP
later in life in the DBA/2J mouse.
These experiments provide new protein targets affected at
pre- and early glaucomatous stages that may provide useful
therapeutic tools for diagnosis or interventions that target
more than IOP. Importantly, aberrant hyperphosphorylation of
cytoskeletal elements, tau, and NF-H, occur prior to complete
loss of anterograde transport and axon loss—supporting the
idea that a therapeutic window exists in which subtle structural
changes may be targeted to potentially prevent loss of function
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or structure. This also suggests that activity of GSK-3β
and other kinases that lead to hyperphosphorylation and
protein translocation/mislocation, along with calpain-induced
spectrin breakdown, are early events with clear mechanisms for
inhibition. Elucidating the timeline and efficacy of drugs affecting
these pathways, therefore, is a promising avenue for future
research aimed at slowing, stopping, or reversing early pathology
and the ultimate neurodegeneration that produces vision loss in
glaucoma.
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